Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BOM:543520'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.39 Med: -0.81 Max: 16.02
Current: 0.93
During the past 8 years, the highest EV-to-FCF of Global Longlife Hospital & Research was 16.02. The lowest was -9.39. And the median was -0.81.
BOM:543520's EV-to-FCF is ranked better than 96.54% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 18.42
vs BOM:543520: 0.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Global Longlife Hospital & Research (BOM:543520) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Global Longlife Hospital & Research's PE Ratio (TTM) for today is calculated as:
Global Longlife Hospital & Research's share price for today is ₹13.04.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Global Longlife Hospital & Research's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-1.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Global Longlife Hospital & Research EV-to-FCF Related Terms
Global Longlife Hospital & Research EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Longlife Hospital & Research EV-to-FCF Chart
For the Medical Care Facilities subindustry, Global Longlife Hospital & Research's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Longlife Hospital & Research EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Global Longlife Hospital & Research's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Global Longlife Hospital & Research's EV-to-FCF falls into.
Global Longlife Hospital & Research's current Enterprise Value is ₹-33.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Global Longlife Hospital & Research's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-45.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Longlife Hospital & Research (BOM:543520) has a EV-to-FCF of 0.74 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Global Longlife Hospital & Research and its competitors. According to the industry distribution chart, Global Longlife Hospital & Research ranks #14 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 3.5%.
Is Global Longlife Hospital & Research's EV-to-FCF too high?
Global Longlife Hospital & Research's current EV-to-FCF is 0.74. The Healthcare Providers & Services industry median EV-to-FCF is 18.42. Global Longlife Hospital & Research's value of 0.74 is 96% below this industry median. Based on the distribution chart, Global Longlife Hospital & Research ranks #14 out of 405 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Global Longlife Hospital & Research has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Global Longlife Hospital & Research's EV-to-FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Global Longlife Hospital & Research ranks #14 out of 405 companies for EV-to-FCF. This places Global Longlife Hospital & Research in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.42. Global Longlife Hospital & Research's value of 0.74 is 96% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.42, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Global Longlife Hospital & Research's current EV-to-FCF of 0.74 is 96% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Global Longlife Hospital & Research and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Longlife Hospital & Research's current EV-to-FCF is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Longlife Hospital & Research stock overvalued right now?
Based on GuruFocus' analysis, Global Longlife Hospital & Research (BOM:543520) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.37, compared to a current price of ₹13.04 — trading 851.8% above its estimated fair value. The current EV-to-FCF is 0.74 and 96% below the Healthcare Providers & Services industry median of 18.42. Global Longlife Hospital & Research's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Global Longlife Hospital & Research (BOM:543520), the current EV-to-FCF is 0.74 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Global Longlife Hospital & Research (BOM:543520) Overvalued in 2026?
Based on GuruFocus' analysis, Global Longlife Hospital & Research stock appears to be overvalued.
The current stock price of ₹13.04 is trading 851.8% above its estimated GF Value™ of ₹1.37.
GuruFocus considers Global Longlife Hospital & Research to be Significantly Overvalued.
Key valuation signals for BOM:543520:
EV-to-FCF: 0.74
GF Value™: ₹1.37 vs. price of ₹13.04 (851.8% above fair value)
Industry Position: 96% below the Healthcare Providers & Services median (#14 of 405)
No single metric tells the full story. See the BOM:543520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Global Longlife Hospital & Research Ltd is Multispecialty Hospital providing Medical & Allied Services. The company operates in the single segment i.e. Health Care and Hospital. Its services are Medical, Surgical, Radiology, Pathology, and Other Services.
36GF Score
Get the complete analysis for BOM:543520
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543520 has been successfully added to your 
